N/A N=182 Less Infections for the Diabetic Foot
Diabetic Foot
Primary: Number of Participants Experiencing Clinical Failure — 26; 30 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=116 Implementation of Telemedicine for Patient With Lower Extremity Wounds
Peripheral Arterial Disease · Peripheral Artery Disease · Peripheral Vascular Diseases
Primary: Specialty Consultation — 66 days
N/A N=272 Evaluation of Closed Incision Negative Pressure Dressing (PREVENA) to Prevent Lower Extremity Amputation Wound Complications
Amputation · Amputation; Postoperative, Sequelae · Wound Dehiscence
Primary: Overall Rate of Wound Complications — 26; 31 Participants
N/A N=150 Negative Pressure Wound Therapy as a Drug Delivery System
Diabetic Foot Ulcers
Primary: Number of Participants Who Achieved Complete Healing or Coverage of the Study Wound — 44; 45 Participants — p=0.87
Phase 2 N=56 The Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With Moderately Infected Foot Ulcers
Diabetic Foot Ulcer
Primary: Number of Participants With a Clinical Cure at Visit 3 (Day 7) — 0; 3 Participants
N/A N=20 CO2-Laser Treatment in Patients With Diabetic Infected Foot Ulcers
Diabetic Foot Ulcer
Primary: Bacterial Load — -99.9; -50.0 Percent change from baseline
N/A N=45 Larval Debridement Therapy Versus Sharp Debridement to Remove Biofilm
Lower Extremity or Diabetic Foot Ulcers · Bacterial Infection
Primary: Total Bacteria Colony Forming Units (CFUs; Natural-log Transformed), With Tryptic Soy Agar (TSA) Plating — 9.6561; 9.6880; 11.9611; 9.1547 Natural Log Transformed…
Phase 2 N=15 Technology That Permits Focal Dose of Antibiotics to be Delivered to Lower Limb(s) of Diabetic Patients
Diabetes · Infection
Primary: Efficacy of Timentin Delivered by PILP Procedure (Treatment Group) Versus Intravenous Delivery (Control Group) at Reducing Microbiological Load in Subjects With…
Phase 2 N=70 Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With a Mild Infection of a Foot Ulcer
Diabetic Foot Ulcer
Primary: Number of Participants With a Clinical Outcome of "Clinical Cure" — 14; 7 Participants
Phase 4 N=21 Wound Management for Sacral Pressure Ulcers With Necrotic Tissue
Pressure Ulcers
Primary: Percentage of Wounds Healed — 63.1; 6.1 percentage of wounds
Phase 3 N=612 Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers
Foot Ulcer, Diabetic · Infection
Primary: Clinical Cure (Resolution of All Clinical Signs and Symptoms of Infection) — 115; 64; 48 Participants
Phase 2 N=175 Preventing Diabetic Foot Ulcers Through Cleaner Feet
Diabetic Foot Ulcer
Primary: Time to New Foot Complication Among All Randomized Participants — 12; 14 Participants
N/A N=20 V.A.C. VeraFlo™ Instillation Therapy vs V.A.C. Ulta™ Therapy on Biofilm in Chronically Infected Wounds
Lower Extremity Wound Infected · Venous Stasis Ulcers
Primary: Change in Bacteria Colony-forming Units Using When NPWT and NPWTi on Venous Leg Ulcers — 8.6; 12.9; 2.5; 3.2 10^3 CFU/g
Phase 3 N=524 Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers
Foot Ulcer, Diabetic · Infection
Primary: Percent of Patients With a Clinical Outcome of Clinical Cure (Resolution of All Clinical Signs and Symptoms of Infection) — 69; 41; 36 percentage of subjects
N/A N=24 Extracorporeal Shockwave Therapy for Diabetic Foot Wounds
Diabetic Foot · Wound
Primary: Wound Volume — 1.16 cm^3
N/A N=15 ICG Fluorescence Imaging in Lower Extremity Amputation Patients
Trauma Injury
Primary: Total Bone Blood Flow (TBBF)-Post Osteotomy — 4.9 mL/min/100g
N/A N=160 Incisional Negative Pressure Wound Therapy for Preoperatively Irradiated Lower Extremity Soft Tissue Sarcoma Wounds
Sarcoma · Cancer · Infectious Disease
Primary: Wound Complication Rate — 3.7; 3.7; 2.1; 2.2 score on a scale
Phase 3 N=189 Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
Diabetic Foot Infection
Primary: Number of Participants With Clinical Response — 43; 63 Participants
Phase 3 N=200 Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
Diabetic Foot Infection
Primary: Number of Participants With Clinical Response — 56; 54 Participants
Phase 2 N=16 Novel Offloading for Diabetic Foot Ulcers With PulseFlow: A Prospective Study
Diabetic Foot Ulcer · Offloading
Primary: Lower Extremity Perfusion Change From Baseline to 4 Weeks — 167; 75 percentage of baseline perfusion
N/A N=9 Repair of Infective Wound Associated With Nerve Defect in the Finger Using A Bipedicled Nerve Flap
Infection Wound · Disruption of Nerve Repair
Primary: 2-point Discrimination Test — 7.5 mm
N/A N=39 Acellular Porcine Dermal Matrix Wound Dressing in the Management of Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Size of Index Wound Based on Calculations Wound Width x Length x Depth 2. Size of Index Wound Based on Calculations Wound Width x Length x Depth — 2.05; 3.33 mm^3
Phase 3 N=68 Efficacy of the Combination of Isosorbide Dinitrate Spray and Chitosan in Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Biopsies — 2.46; 2.64; 2.56; 2.07 UI/dL
N/A N=105 Prevena™ vs Dermabond in Groin Wound Infections in Vascular Surgery
Wound Infection
Primary: Comparison of Healing of Groin Wounds Between Patients Treated With Prevena vs Dermabond — 41; 54 Participants
Phase 4 N=6,785 Pre-operative Alcohol Skin Solutions in Fractured Extremities
Surgical Site Infection · Unplanned Fracture-Related Reoperation · Open Appendicular Fracture
Primary: Number of Participants With a Superficial Incisional Surgical Site Infection (SSI) — 20; 27; 6; 9 Participants
N/A N=298 Prevena™ Incisional Negative Pressure Wound Therapy in Re-operative Colorectal Surgery
Surgical Site Infection
Primary: Occurrence of Superficial Surgical Site Infection — 11; 21; 107; 128 Participants
Phase 3 N=130 Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Number of 100% Wound Closure — 55.74; 50.82 percentage of patients
N/A N=48 Evaluating the Safety and Efficacy of Fractionated Carbon Dioxide Therapy in Postoperative Lower Extremity Wound Healing
Leg Ulcer
Primary: Number of Participants With Completely Healed Lower Extremity Wounds — 20; 18 Participants
N/A N=164 Negative Pressure Wound Therapy to Reduce Surgical Site Infection
Patients Undergoing Hepatopancreatobiliary Surgery
Primary: Participants With a Surgical Site Infection — 14; 20 Participants — p=0.27
Phase 4 N=88 Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection
Diabetic Foot Ulcer
Primary: Clinical Cure — 38; 39 participants